Share
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in OI
October 7, 2024
The OI Foundation would like to bring your attention to an update from Ultragenyx!
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
CLICK HERE TO VIEW THE PRESS RELEASE
Was this helpful?
Thanks for your feedback!